Radiation Therapy of Benign Tumors, Hyperplasias, and Dermatoses

1991 ◽  
pp. 139-145 ◽  
Author(s):  
Renato G. Panizzon
Keyword(s):  
Radiation Therapy ◽  
Benign Tumors

scholarly journals Factors Associated with and Temporal Trends in the Use of Radiation Therapy for the Treatment of Pituitary Adenoma in the National Cancer Database

2019 ◽  
Author(s):  
Ramie Fathy ◽  
Edward Kuan ◽  
John Y. K. Lee ◽  
M Sean Grady ◽  
Michelle Alonso-Basanta ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Pituitary Adenoma ◽  
Retrospective Analysis ◽  
Pituitary Adenomas ◽  
Temporal Trends ◽  
Benign Tumors ◽  
National Cancer Database ◽  
Cancer Program ◽  
To Receive ◽  
Over Time

Abstract Purpose Radiation therapy represents an uncommon but important component of treatment plans for some pituitary adenomas (PAs). Although radiation therapy has been used to treat pituitary adenomas for over a century, general trends in the usage of radiation therapy for this purpose have not been reviewed. Additionally, there are few large studies evaluating how radiation therapy is used for the treatment of these benign tumors. Investigating these trends and identifying any variations in radiation therapy utilization would help to better inform treatment decisions and improve patient outcomes. Design Present study is a retrospective analysis of cases using the National Cancer Database. Setting The research was organized at a tertiary academic medical center. Participants Patients were diagnosed with pituitary adenoma between 2004 and 2014 within the National Cancer Database (NCDB). Methods Temporal trends in the usage of radiation therapy to treat pituitary adenoma were analyzed through a retrospective analysis of 77,142 pituitary adenoma cases from the NCDB between 2004 and 2014. Univariate and multivariate analyses were to examine the relationship between patient, tumor, and treatment factors, and the incorporation of radiation therapy into the treatment of pituitary adenomas. We adjusted for potential confounders such as age, sex, race, comorbidity score, facility type, and year of diagnosis. Results A total of 77,142 patients met inclusion criteria. Inclusion of radiation therapy in pituitary adenoma treatment was 8.0% in 2004 and steadily declined to a low of 3.1% in 2014. Overall, patients were less likely to receive radiation for their pituitary adenoma over time (p < 0.001). Similarly, patients were found to be less likely to receive any type of treatment for PA over time (p < 0.001). Multivariable evaluation found patients who were female, between 54 and 64 years of age, or treated at either a Comprehensive Community Cancer Program or an Integrated Network Cancer Program were more likely to receive radiation as part of their pituitary adenoma treatment (p < 0.001, odds ratio [OR] = 2.01, confidence interval [CI]: 1.54–2.63; p < 0.001, OR = 1.84, CI: 1.38–2.44, respectively). Patients were less likely to receive radiation for their PA if they were African American (p < 0.001, OR = 0.81, CI: 0.72–0.91). Logistic regression also identified a progressive increase in the likelihood of receiving radiation after a PA diagnosis with increasing tumor size starting with microscopic tumors, peaking at 4 to 5 cm (p < 0.001; OR = 15.57; CI: 12.20–19.87). Conclusion In this sample of pituitary adenoma patients treated at NCDB institutions between 2004 and 2014, we found a steady decline in the incorporation of radiation therapy in treatment, as well as in the use of any type of intervention for PA treatment, suggesting a rise in noninterventional observation of PA.

scholarly journals P03.14 New features of modern 3D conformal external radiotherapy (RT) of benign head tumors in children

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii28-iii28
Author(s):  
F Antonenko ◽  
E Slobina ◽  
E Abbasova ◽  
A Smyslov ◽  
A Dykina ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Total Dose ◽  
Skull Base ◽  
High Precision ◽  
New Technologies ◽  
Clinical Symptoms ◽  
Benign Tumors ◽  
Scientific Center ◽  
Head Tumors ◽  
Surgical Methods

Abstract BACKGROUND demonstrate the possibilities of radiation therapy (LT) in children with benign head tumors using IMRT, VMAT, IGRT techniques - high-precision modern 3D conformal radiation therapy MATERIAL AND METHODS From 1990 to 2007 for the first time in Russia, 88 children with juvenile angiofibromas were treated in Russian Scientific Center of Roentgenoradiology. The studies were carried out on the gamma-therapeutic apparatus “AGAT-P1” and on the linear accelerator “Phillips SL75” Total dose was 35–45 Gy. In 2014–2018 we treated 29 patients aged 3–17 years with benign tumors of the skull base and brain (angiofibromas, craniopharyngiomas, hemangiomas) using high-precision techniques (IMRT, VMAT, IGRT). 15 of 29 patients were repeatedly operated in various domestic and foreign clinics and were admitted to RT with the threat of bleeding, with recurrent growth of tumors, including after multiple selective angioembolization. RESULTS Up to 80% of patients had a 5-year stable remission, and the optimal total dose for radiation therapy of benign head tumors in children was scientifically substantiated. It was found that there is a high risk of continued growth after RT in children under 8 years of age, complications in 10% of patients in the coming years after RT and in 100% of those reirradiated. In all 29 cases of RT in children, we observed a positive clinical effect - stopping bleeding from the nasopharynx after 1–3 sessions of 3D conformal RT (Dose per fraction 1.8 Gy, total dose 45–54 Gy), positive clinical symptoms under the supervision of an Head and Neck surgeon. The effect of hardening and stopping the growth of tumors according to MRI data were followed up after 3 months, 6 months, 1 year. CONCLUSION The development of navigational, endosurgical and fibro-endoscopic minimally invasive technologies in the last 30 years has allowed to expand the indications for surgical methods of treatment for benign head tumors in children, which has reduced their flow to RT. However, after modern surgical interventions, 6–10% of these patients experience recurrences and bleeding, the number of which can be reduced with timely RT. New technologies in LT provide minimal impact on surrounding healthy tissues and allow wider use of RT in recurrent and difficult-to-reach benign skull base tumors in children

Factors associated with survival in patients with meningioma

1998 ◽  
Vol 88 (5) ◽  
pp. 831-839 ◽  
Author(s):  
Bridget J. McCarthy ◽  
Faith G. Davis ◽  
Sally Freels ◽  
Tanya S. Surawicz ◽  
Denise M. Damek ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Proportional Hazards Model ◽  
Malignant Tumors ◽  
Age At Diagnosis ◽  
Benign Tumors ◽  
Content Type ◽  
Cancer Data ◽  
Fine Print

Object. To explore factors affecting the survival rate in patients with meningiomas, the authors used the National Cancer Data Base (NCDB), which includes tumors from approximately 1000 hospitals participating in the American College of Surgeons tumor registry program. Methods. Analysis included over 9000 cases diagnosed from 1985 to 1988 and 1990 to 1992. Survival estimates were computed and prognostic factors were identified using a proportional hazards model. The overall 5-year survival rate was 69% and it declined with patient age. This rate was 81% in patients aged 21 to 64 years and 56% for patients 65 years of age or older. When patients were grouped by the histological type of their tumors, those with benign tumors had an overall 5-year survival rate of 70%, whereas the overall 5-year survival rates in patients with atypical and malignant meningiomas were 75% and 55%, respectively. Prognostic factors for benign tumors included age at diagnosis, tumor size, whether treated surgically, hospital type, and radiation therapy; for malignant tumors, the prognostic factors included: age at diagnosis, whether treated surgically, and radiation therapy. These factors were statistically significant. The 5-year rate for recurrence of symptoms (regardless of the method of treatment) was 19.2% for those with benign tumors and 32.4% for those with malignant tumors. In patients whose benign tumor had been completely removed, the 5-year rate of tumor recurrence was 20.5%. Conclusions. Although not population-based, the NCDB has the potential for providing pertinent information regarding patient characteristics and methods of treatment for benign, as well as malignant, brain tumors.

Multiple meningiomas following radiation therapy for medulloblastoma

1981 ◽  
Vol 55 (2) ◽  
pp. 282-286 ◽  
Author(s):  
Robert P. Iacono ◽  
Michael L. J. Apuzzo ◽  
Richard L. Davis ◽  
Fong Y. Tsai
Keyword(s):  
Radiation Therapy ◽  
Statistical Data ◽  
Benign Tumors ◽  
Content Type ◽  
Multiple Meningiomas ◽  
Radiation Induced ◽  
Fine Print

✓ A patient is reported who was found to harbor multiple benign meningiomas 27 years after radiation therapy for medulloblastoma. Thirty-eight cases of meningiomas occurring after radiation are reviewed and analyzed. Statistical data from these cases support the concept of radiation-induced benign tumors.

Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors

2008 ◽  
Vol 24 (5) ◽  
pp. E2 ◽  
Author(s):  
Walter D. Johnson ◽  
Lilia N. Loredo ◽  
Jerry D. Slater
Keyword(s):  
Radiation Therapy ◽  
Survival Rates ◽  
Tumor Resection ◽  
Radical Resection ◽  
Benign Tumors ◽  
Tumor Control ◽  
Tumor Type ◽  
Secondary Treatment ◽  
Intracranial Tumors ◽  
Postoperative Radiation Therapy

✓ Historically, radiation therapy has been used extensively in the treatment of malignant and aggressive intracranial tumors, and the importance of its role has been repeatedly verified by prolonged patient survival rates and increased tumor control. As more modern capabilities are employed in surgery and radiotherapy, attention is being directed to the utility of radiation as either primary or secondary treatment of benign tumors. Specifically, primary treatment encompasses irradiation of small benign tumors without biopsy confirmation of tumor type; secondary treatment involves postoperative radiation therapy, with the possibility that less-aggressive tumor resection may be performed in areas that have a higher probability of resultant neurological deficit. Current literature suggests that this is not only a possible treatment strategy, but that it may be superior to more radical resection in some cases, for example, in vestibular schwannomas and meningiomas. This article provides an overview of factors to consider in the use of radiation therapy and reviews the relationships between radiation and surgery, notably the unique complementary role each plays in the treatment of benign intracranial tumors.

Neurologic Complications of Radiation Therapy and Chemotherapy

2021 ◽  
pp. 967-973
Author(s):  
Gretchen E. Schlosser Covell ◽  
Akanksha Sharma ◽  
Alyx B. Porter
Keyword(s):  
Radiation Therapy ◽  
Adverse Effects ◽  
Pituitary Tumors ◽  
High Grade Glioma ◽  
External Beam Radiation ◽  
Benign Tumors ◽  
Beam Radiation ◽  
Brain And Spinal Cord ◽  
Malignant And Benign Tumors ◽  
The Brain

Separate from neurosurgery, radiation and chemotherapy have been used in the treatment of malignant and benign tumors of the brain and spinal cord. Although effective, the treatments can be associated with serious neurologic adverse effects. This chapter reviews the adverse effects of these treatments. External beam radiation therapy (RT) is a common mode of radiation and is most effective for high-grade glioma. Intensity-modulated RT and stereotactic radiosurgery are usually reserved for pituitary tumors, skull-base masses, metastatic disease, and primary parenchymal tumors.

scholarly journals Factors associated with survival in patients with meningioma

1997 ◽  
Vol 2 (4) ◽  
pp. E3 ◽  
Author(s):  
Bridget J. McCarthy ◽  
Faith Davis ◽  
Sally Freels ◽  
Tanya S. Surawicz ◽  
Denise Damek ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Program Analysis ◽  
Proportional Hazards ◽  
Proportional Hazards Model ◽  
Malignant Tumors ◽  
Survival Rates ◽  
Age At Diagnosis ◽  
Benign Tumors

Factors affecting the survival rate in patients with meningiomas were explored using the National Cancer Database (NCDB), which includes tumors from approximately 1000 hospitals participating in the American College of Surgeons tumor registry program. Analysis included over 9000 cases diagnosed from 1985 to 1988 and 1990 to 1992. Survival estimates were computed and prognostic factors were identified using a proportional hazards model. The overall 5-year survival rate was 69% and it declined with age. This rate was 81% in patients aged 21 to 64 and 56% for patients 65 years of age or older. When patients were grouped by the histological type of their tumors, those with benign tumors had an overall 5-year survival rate of 70%, whereas the overall 5-year survival rates in patients with atypical and malignant meningiomas were 75% and 55%, respectively. Prognostic factors for benign tumors included age at diagnosis, tumor size, whether treated surgically, hospital type, and radiation therapy; for malignant tumors, age at diagnosis, whether treated surgically, and radiation therapy were statistically significant. The 5-year rate for recurrence of symptoms (regardless of the method of treatment) was 18.2% for those with benign tumors and 27.5% for those with malignant tumors. In patients whose benign tumor had been completely removed, the 5-year rate of tumor recurrence was 20.5%. Although not population-based, the NCDB has the potential for providing pertinent information regarding patient characteristics and methods of treatment for benign, as well as malignant, brain tumors.

scholarly journals Stereotactic single high dose radiation therapy for benign tumors of the brain

1989 ◽  
Vol 17 ◽  
pp. 195 ◽  
Author(s):  
R. Engenhart ◽  
B. Kimmig ◽  
K.H. Höver ◽  
B. Wowral ◽  
V. Sturm ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Benign Tumors ◽  
High Dose ◽  
Single High Dose ◽  
The Brain ◽  
Dose Radiation

INNV-23. CASE REPORT OF CISPLATIN + ETOPOSIDE FOR THE TREATMENT OF METASTATIC MALIGNANT MENINGIOMA

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi110-vi110
Author(s):  
Minhdan Nguyen ◽  
Judy Truong ◽  
Akanksha Sharma ◽  
Santosh Kesari ◽  
Jose Carrillo ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Vision Loss ◽  
Performance Status ◽  
Benign Tumors ◽  
Rapid Progression ◽  
Malignant Meningioma ◽  
Mri Imaging ◽  
Who Grade ◽  
Repeat Resection ◽  
The Subject

Abstract INTRODUCTION Meningioma have an annual incidence of 5 per 100,000 and is the most frequent primary tumor of the central nervous system. Risk factors include radiotherapy and hormone intake. Most meningioma are grade I benign tumors, but up to 15% are atypical and 2% anaplastic according to the WHO 2016 histological criteria. Extra-CNS metastasis is exceedingly rare but carry a poor prognosis. Surgical resection and radiation therapy are the only approved therapies for the treatment of high grade or recurrent meningioma. Chemotherapy options have been limited and none have shown significant response rates. METHODS We report a case of a 33 year old male with an anaplastic meningioma (WHO Grade III) with metastasis to the lungs and rapid progression despite repeat resection. The subject was previously treated with resection and radiation therapy to a skull base/sinonasal lesion. Progression occurred at anterior cranial fossa, which required repeat resection. Within a month, the meningioma showed substantial progression with invasion into the orbit and nasopharynx as well as metastasis to the lung. The subject experienced significant clinical decline which included bilateral vision loss. The subject was treated with Cisplatin and Etoposide for 4 cycles. RESULTS The patient had immediate clinical improvement after the first cycle. Repeat MRI imaging of the brain showed partial response with approximately 40% tumor reduction, and CT of the chest showed complete response. The subject’s performance status also improved significantly with treatment including recovery of eyesight bilaterally. CONCLUSION This case showed that the use of Cisplatin + Etoposide for metastatic malignant meningioma can have significant objective and clinical response. The use of this regimen warrants further investigation. A clinical trial is currently being developed.

scholarly journals Clinical Outcomes in Patients With NFPAs Treated With Stereotactic Linear Accelerator Radiation Therapy

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A641-A641
Author(s):  
Karla Krystel Ordaz-Candelario ◽  
Juan Pablo Godoy-Alonso ◽  
Marlon Vladimir Vázquez-Aguirre ◽  
German Gonzalez-De-la-Cruz ◽  
Juanita Silva-Serrano ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Radiation Therapy ◽  
Linear Accelerator ◽  
Benign Tumors ◽  
First Line ◽  
Surgical Recurrence ◽  
Safe Strategy ◽  
The Mean

Abstract Background: Non-functioning pituitary adenoma (NFPAs) are benign tumors of the pituitary gland characterized by the absence of hormonal hypersecretion. Surgical treatment and fractionated stereotactic radiotherapy (FSRT) are necessary in majority of patients. NFPAs appear to cause higher mortality compared to the general population. Objective: To assess outcomes in patients with NFPAs treated with stereotactic linear accelerator radiation therapy. Material and Methods: Comparative, observational, longitudinal study, with prolective evaluation, from January 1987 to August 2019. Results: 264 patients (65.5% women and 34.5% men, mean age 43 ± 16 years) with a diagnosis of non-functional adenomas were evaluated. 30 patients received FSRT (14%), 93% were macroadenomas, and 80% of the cases were operated as a first line of treatment. The mean number of surgeries before radiotherapy was 1.2+-.847 (0-4). FSRT were used in 91.7% (n=21) because of post-surgical recurrence. Diabetes insipidus after surgery was transitory in 5.4%, and persistent in 4.0%. Hypopituitarism was identified in 59.4% before radiation (n=19), and in 13 patients (7.7%) after mean of 6.5+-5.5 years of FSRT. Dyslipidemia (62.0% vs. 45.9%), high blood pressure (16.5% vs. 23%), type 2 diabetes mellitus (10% vs. 77%) and heart failure (10% vs. 8.4%) were observed in the irradiated vs. non-irradiated groups, respectively (p&lt;0.05). Conclusions: FSRT is a useful and safe strategy as an adjuvant treatment in patients with NFPA.

Sign in / Sign up

Export Citation Format

Share Document